Inovio and U.S. Army Co-developing Novel Vaccine That Completely Prevents Lethal Lassa Fever Infection in Pre-Clinical Study...
October 24 2017 - 8:00AM
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced results
of a study in which a DNA vaccine provided 100% protection for
non-human primates challenged with a lethal dose of the Lassa fever
virus. Lassa is a virulent hemorrhagic virus, similar to Ebola,
which infects approximately 300,000 people annually. These
results were published in the most recent issue of Human Vaccines
& Immunotherapeutics in an article entitled, “A DNA Vaccine
Delivered by Dermal Electroporation Fully Protects Cynomolgus
Macaques Against Lassa Fever,” by Inovio researchers and U.S. Army
collaborators.
In the study, funded by a previously awarded
$3.5 million grant from the National Institute of Allergy and
Infectious Diseases (NIAID), the animals first received Inovio’s
DNA vaccine against Lassa hemorrhagic fever via intradermal
administration with CELLECTRA® delivery device. The animals were
then challenged with a lethal dose of the Lassa virus. All of
the animals survived; in fact, none of the vaccinated animals
displayed any signs of disease.
Dr. J. Joseph Kim, Inovio's President and Chief
Executive Officer, said, “Inovio demonstrates our full commitment
to global public health in this innovative public/private
partnership against a virulent virus with pandemic and bioterror
potential. Our DNA-based platform is especially well-suited to
rapidly respond to viral outbreaks and newly emerging pathogens due
to its safety profile, ease and speed of development and
manufacturing as well as the ability to be shipped and stored
without a cold-chain environment. Inovio has shown these attributes
most recently as the first organization to produce Zika and MERS
vaccines and the first to report positive human data from these
vaccine trials. Inovio will continue to lead in the global efforts
to protect the world from multiple epidemic threats.”
Inovio is collaborating with Dr. Connie
Schmaljohn, Chief Scientist at the U.S. Army Medical Research
Institute of Infectious Diseases (USAMRIID) and her group. The goal
of this public/private partnership is to develop vaccines that
would facilitate rapid vaccination of U.S. troops stationed around
the world against multiple deadly infectious diseases and protect
civilian populations from pandemic and bioterror threats.
Lassa fever is an acute disease that annually
infects up to 300,000 people, mostly in Central and West Africa
regions. The disease can cause fever and hemorrhaging of various
parts of the body -- including the eyes and nose -- and can be
spread through contact with an infected rat. Person to person
transmission is also possible, albeit less common. Immediate deaths
from the infection are approximately 5,000 per year, but based on
serologic surveys the estimated fatality rate is more than 50% of
Lassa infected people because the infection can persist for at
least one year after infection.
Because of rapid and wide global travel and
commerce, Lassa is not only a major health threat in Africa, but
throughout the world. Lassa virus has been classified as a
Category A biological threat agent by the U.S. Centers for Disease
Control and Prevention. Along with MERS and Nipah, Lassa
virus has been selected as the top potential global epidemic
targets for new vaccine development by the newly-formed
multi-billion dollar, Coalition for Epidemic Preparedness
Initiative (CEPI) in 2017.
About Inovio Pharmaceuticals,
Inc.
Inovio is taking immunotherapy to the next level
in the fight against cancer and infectious diseases. We are the
only immunotherapy company that has reported generating T cells in
vivo in high quantity that are fully functional and whose killing
capacity correlates with relevant clinical outcomes with a
favorable safety profile. With an expanding portfolio of immune
therapies, the company is advancing a growing preclinical and
clinical stage product pipeline. Partners and collaborators include
MedImmune, The Wistar Institute, University of Pennsylvania, DARPA,
GeneOne Life Science, Plumbline Life Sciences, ApolloBio
Corporation, Drexel University, NIH, HIV Vaccines Trial Network,
National Cancer Institute, U.S. Military HIV Research Program, and
Laval University. For more information, visit www.inovio.com.
This press release contains certain
forward-looking statements relating to our business, including our
plans to develop electroporation-based drug and gene delivery
technologies and DNA vaccines, our expectations regarding our
research and development programs, including the planned initiation
and conduct of clinical trials and the availability and timing of
data from those trials, and the sufficiency of our capital
resources. Actual events or results may differ from the
expectations set forth herein as a result of a number of factors,
including uncertainties inherent in pre-clinical studies, clinical
trials and product development programs, the availability of
funding to support continuing research and studies in an effort to
prove safety and efficacy of electroporation technology as a
delivery mechanism or develop viable DNA vaccines, our ability to
support our pipeline of SynCon® active immunotherapy and vaccine
products, the ability of our collaborators to attain development
and commercial milestones for products we license and product sales
that will enable us to receive future payments and royalties, the
adequacy of our capital resources, the availability or potential
availability of alternative therapies or treatments for the
conditions targeted by the company or its collaborators, including
alternatives that may be more efficacious or cost effective than
any therapy or treatment that the company and its collaborators
hope to develop, issues involving product liability, issues
involving patents and whether they or licenses to them will provide
the company with meaningful protection from others using the
covered technologies, whether such proprietary rights are
enforceable or defensible or infringe or allegedly infringe on
rights of others or can withstand claims of invalidity and whether
the company can finance or devote other significant resources that
may be necessary to prosecute, protect or defend them, the level of
corporate expenditures, assessments of the company's technology by
potential corporate or other partners or collaborators, capital
market conditions, the impact of government healthcare proposals
and other factors set forth in our Annual Report on Form 10-K for
the year ended December 31, 2016, our Form 10-Q for the
period ended June 30, 2017, and other regulatory filings we make
from time to time. There can be no assurance that any product
candidate in Inovio's pipeline will be successfully developed,
manufactured or commercialized, that final results of clinical
trials will be supportive of regulatory approvals required to
market licensed products, or that any of the forward-looking
information provided herein will be proven accurate. In addition,
the forward-looking statements included in this press release
represent Inovio’s views as of the date hereof. Inovio anticipates
that subsequent events and developments may cause its views to
change. However, while Inovio may elect to update these
forward-looking statements at some point in the future, the company
specifically disclaims any obligation to do so, except as may be
required by law. These forward-looking statements should not be
relied upon as representing Inovio’s views as of any date
subsequent to the date of this release.
CONTACTS:
Investors/Media: Jeff Richardson, Inovio Pharmaceuticals,
267-440-4211, jrichardson@inovio.com
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Apr 2023 to Apr 2024